Exact Mass: 433.1454
Exact Mass Matches: 433.1454
Found 93 metabolites which its exact mass value is equals to given mass value 433.1454
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Tolmetin glucuronide
Tolmetin glucuronide belongs to the family of Glucuronic Acid Derivatives. These are compounds containing a glucuronic acid moeity (or a derivative), which consists of a glucose moiety with the C6 carbon oxidized to a carboxylic acid.
4-Hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine
4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is an acylcarnitine. More specifically, it is an 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
N-(((1-(2-(Diethylamino)ethyl)amino)-9-oxo-9H-thioxanthen-4-yl)methyl)methanesulfonamide
Ala Asn Asp Asp
Dihydrozeatin riboside-5-monophosphate sodium salt
12-[(2,4-dimethoxyphenyl)carbonyl]-6a,6b,10,11,11a,12-hexahydro-8,11-epoxyoxepino[4,5:3,4]pyrrolo[1,2-a]quinolin-7(8H)-one
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.276 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.275 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.279
Ala Asp Asp Asn
Ala Asp Asn Asp
Mefenamic acid Metabolite (b-D-Glucopyranuronic acid, 1-[2-[[3-(hydroxymethyl)-2-methylphenyl]amino]
Asp Ala Asp Asn
Asp Ala Asn Asp
Asp Asp Ala Asn
Asp Asp Gly Gln
Asp Asp Asn Ala
Asp Asp Gln Gly
Asp Glu Gly Asn
Asp Glu Asn Gly
Asp Gly Asp Gln
Asp Gly Glu Asn
Asp Gly Asn Glu
Asp Gly Gln Asp
Asp Asn Ala Asp
Asp Asn Asp Ala
Asp Asn Glu Gly
Asp Asn Gly Glu
Asp Gln Asp Gly
Asp Gln Gly Asp
Glu Asp Gly Asn
Glu Asp Asn Gly
Glu Gly Asp Asn
Glu Gly Asn Asp
Glu Asn Asp Gly
Glu Asn Gly Asp
Gly Asp Asp Gln
Gly Asp Glu Asn
Gly Asp Asn Glu
Gly Asp Gln Asp
Gly Glu Asp Asn
Gly Glu Asn Asp
Gly Asn Asp Glu
Gly Asn Glu Asp
Gly Gln Asp Asp
Asn Ala Asp Asp
Asn Asp Ala Asp
Asn Asp Asp Ala
Asn Asp Glu Gly
Asn Asp Gly Glu
Asn Glu Asp Gly
Asn Glu Gly Asp
Asn Gly Asp Glu
Asn Gly Glu Asp
Gln Asp Asp Gly
Gln Asp Gly Asp
Gln Gly Asp Asp
Tolmetin glucuronide
(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Methoxy-4-Methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide
2-[2-[4-[(2-chloroethyl)methylamino]phenyl]vinyl]-1,3,3-trimethyl-3H-indolium dihydrogen phosphate
9-AMino-(9-deoxy)epi-dihydroquinine trihydrochloride
Hydroxychloroquine sulfate
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018501 - Antirheumatic Agents D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
N-(((1-(2-(Diethylamino)ethyl)amino)-9-oxo-9H-thioxanthen-4-yl)methyl)methanesulfonamide
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
N-(3-chloropyridin-2-yl)-N-[(3R)-piperidin-3-yl]-4-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)benzamide
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
4-Hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine
2-[[7-(4-Methoxyphenyl)-5-phenyl-4-pyrrolo[2,3-d]pyrimidinyl]thio]propanoic acid ethyl ester
3-[2-[(1,5-Dimethyl-3-oxo-2-phenyl-4-pyrazolyl)amino]-2-oxoethyl]-4-oxo-1-phthalazinecarboxylic acid
[1-[1-[4-(difluoromethoxy)phenyl]-2,5-dimethylpyrrol-3-yl]-1-oxopropan-2-yl] 6-oxo-4,5-dihydro-1H-pyridazine-3-carboxylate
1-(4-methylphenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea
N-[(2R,3S,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2R,3R,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2R,3S,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2R,3R,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2S,3S,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2S,3S,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2S,3R,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2S,3R,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
5-(3,4-Dimethoxyphenyl)-4-(furan-2-carbonyl)-1-(2-phenylethyl)pyrrolidine-2,3-dione
G907
G907 is a selective antagonist of ATP-binding cassette (ABC) transporter MsbA with anti-microbial activity. G907 inhibits E. coli MsbA with an IC50 value of 18 nM. G907 traps MsbA in an inward-facing, lipopolysaccharide-bound conformation by wedging into an architecturally conserved transmembrane pocket[1][2].
PHT-7.3
PHT-7.3 is a selective inhibitor of connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain (Kd=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity[1].